Bio-Techne Corp.
(NASDAQ : TECH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 9.79%424.330.0%$8556.04m
BNTXBioNTech SE 16.31%409.190.0%$1502.83m
NVAXNovavax, Inc. 21.93%229.9279.8%$808.62m
SNSSSunesis Pharmaceuticals, Inc. -1.66%10.640.7%$743.78m
AMGNAmgen, Inc. -6.09%229.211.3%$475.94m
BIIBBiogen, Inc. -0.14%337.541.7%$453.20m
VRTXVertex Pharmaceuticals, Inc. 0.67%201.391.9%$423.27m
GILDGilead Sciences, Inc. -0.40%69.551.0%$408.62m
REGNRegeneron Pharmaceuticals, Inc. 1.27%593.982.7%$324.29m
ILMNIllumina, Inc. 0.45%500.653.5%$261.30m
NTLAIntellia Therapeutics, Inc. -1.24%137.072.3%$190.45m
CRSPCRISPR Therapeutics AG 0.96%122.590.6%$136.47m
SGENSeagen Inc. 2.60%162.305.8%$134.14m
EXASEXACT Sciences Corp. 1.82%106.1118.1%$130.59m
BGNEBeiGene Ltd. 1.27%345.781.3%$130.55m

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded on 1976 and is headquartered in Minneapolis, MN.